ALBAWABA - An unexpected setback to the burgeoning effort to bring psychedelics out of the shadows as a new therapeutic option for post-traumatic stress disorder (PTSD) was handed down as the US FDA rejected a proposal to allow Lykos Therapeutics' MDMA-based medication to be used in conjunction with talk therapy. MDMA, frequently referred to as ecstasy or molly, has been promoted in several medical circles as a therapeutic aid for ...